Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Income from Continuing Operations (2016 - 2025)

BioCorRx (BICX) has disclosed Income from Continuing Operations for 16 consecutive years, with 471218.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 61.62% to 471218.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2703088.0 through Dec 2025, up 48.14% year-over-year, with the annual reading at 3508763.0 for FY2025, 32.68% up from the prior year.
  • Income from Continuing Operations hit 471218.0 in Q4 2025 for BioCorRx, down from 2830.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2830.0 in Q3 2025 to a low of 1584063.0 in Q1 2021.
  • Historically, Income from Continuing Operations has averaged 1063210.75 across 5 years, with a median of 1108405.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: crashed 74.44% in 2024 and later skyrocketed 99.81% in 2025.
  • Year by year, Income from Continuing Operations stood at 1203299.0 in 2021, then increased by 3.96% to 1155597.0 in 2022, then rose by 16.15% to 969009.0 in 2023, then dropped by 26.69% to 1227633.0 in 2024, then skyrocketed by 61.62% to 471218.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BICX at 471218.0 in Q4 2025, 2830.0 in Q3 2025, and 1377276.0 in Q2 2025.